Xuanyao He

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et al. · The Lancet Oncology · 2023 · 82 citations

First-line Cemiplimab Monotherapy, Empower-lung 1, Medicine +10

Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values

Christopher Whaley, Wei Lu, Stefanie Painter et al. · Journal of Medical Economics · 2019 · 54 citations · Full text

Glucagon Prescription Patterns In Patients With Either Type 1 Or 2 Diabetes With Newly Prescribed Insulin

Beth Mitchell, Xuanyao He, Ian M. Sturdy et al. · Endocrine Practice · 2015 · 46 citations

Metabolic Syndrome, Diabetes Management, Newly Prescribed Insulin +7

Estimating Individualized Treatment Rules for Ordinal Treatments

Jingxiang Chen, Haoda Fu, Xuanyao He et al. · Biometrics · 2018 · 32 citations · Full text

Multicategory Outcome Weighted Margin-based Learning for Estimating Individualized Treatment Rules

Chong Zhang, Jingxiang Chen, Haoda Fu et al. · Statistica Sinica · 2018 · 26 citations · Full text